Pfizer and BioNTech have begun testing a separate COVID-19 vaccine that is specially adapted to the omicron variant.
The trial will take place among 1,420 people in the age range from 18 to 55 years of age. The goal is to examine the immune response of the participants who receive the dose.
Pfizer chief Albert Bourla has previously stated that the vaccine should be ready for approval by professional authorities by the end of March.
The reason for the development of the new vaccine is that the protection of existing vaccines against the mild and moderate disease course of the coronavirus seems to be worse when it comes to the omicron variant.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at [email protected]
Be the first to comment on "Pfizer and BioNTech begin omicron vaccine trial"